IL6R阻断治疗脓毒症及脓毒症相关死亡的治疗潜力:一项孟德尔随机化研究
研究采用孟德尔随机化方法,以IL6R及附近单核苷酸多态性为工具,评估IL6R阻断对脓毒症及其严重程度的因果效应。在英国生物银行队列(N=486,484,含11,643例脓毒症)中,IL6R阻断与脓毒症风险降低相关(OR=0.80;95%CI 0.66至0.96),对28天脓毒症死亡、脓毒症重症监护入住及重症监护死亡的效应方向一致但部分估计不精确;对重症COVID-19的保护效应与脓毒症相似。作者建议应考虑在脓毒症中开展IL-6受体拮抗剂的随机试验。
要点
- 在英国生物银行队列中,IL6R阻断与脓毒症风险降低相关(OR=0.80;95%CI 0.66至0.96)。
- 对脓毒症重症监护入住(OR=0.48;95%CI 0.30至0.78)和重症监护死亡(OR=0.37;95%CI 0.14至0.98)的效应更大。
- 在COVID-19 HGI中确认IL6R阻断对重症COVID-19的保护效应(OR=0.69;95%CI 0.57至0.84)。
核心结论
- IL6R阻断与脓毒症发生率降低存在因果关联;对脓毒症相关死亡和脓毒症重症监护入住也有方向一致的因果效应支持,但估计不精确。
- 这些效应与在重症COVID-19中观察到的效应大小相当;数据提示应考虑在脓毒症中开展IL-6受体拮抗剂的随机试验。
研究设计与样本
- 采用孟德尔随机化分析,使用IL6R基因内及附近的单核苷酸多态性作为工具变量,以对C反应蛋白(CRP)的效应加权,并通过逆方差加权荟萃分析合并结果,以代理IL6R阻断的效应。
- 主要结局为脓毒症,次要结局包括脓毒症严重程度、其他感染和COVID-19;结局在UK Biobank、FinnGen、COVID-19 Host Genetics Initiative(HGI)以及GenOSept和GainS联盟中测量。
- UK Biobank队列样本量为486,484例,其中11,643例患有脓毒症。
- 进行了多项敏感性分析以检验方法假设,包括利用CRP和gp130附近变异进行类似分析。
主要发现
- 在UK Biobank队列中,IL6R阻断与主要结局脓毒症风险降低相关(OR=0.80;95%CI 0.66至0.96,按自然对数转换的CRP降低每单位计)。
- 效应大小随严重程度增加:对28天脓毒症死亡的OR=0.74(95%CI 0.47至1.15);对脓毒症重症监护入住的OR=0.48(95%CI 0.30至0.78);对脓毒症重症监护死亡的OR=0.37(95%CI 0.14至0.98)。
- 在GainS和GenOSept联盟中,与严重呼吸道感染也可见类似关联:重症监护中肺炎的OR=0.69(95%CI 0.49至0.97),重症监护中脓毒症生存的OR=0.22(95%CI 0.04至1.31),但该结果精确度很低。
- 在COVID-19 HGI中,确认了先前报道的IL6R阻断对重症COVID-19的保护效应(OR=0.69;95%CI 0.57至0.84),其大小与脓毒症中所见相似。
- 敏感性分析未改变主要结果。
临床怎么用
- 作者认为,数据提示应考虑在脓毒症中开展IL-6受体拮抗剂的随机试验。
局限性
- 结果受孟德尔随机化的局限性和假设约束,此处反映的是将这些单核苷酸多态性效应解释为通过阻断IL6R因果起作用。
- 结果反映的是终生暴露于IL6R阻断的效应,而非治疗性IL6R阻断的效应。
- 在GainS和GenOSept联盟中,重症监护中脓毒症生存的结果精确度很低(OR=0.22;95%CI 0.04至1.31)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sepsis is characterised by dysregulated, life-threatening immune responses, which are thought to be driven by cytokines such as interleukin 6 (IL-6). Genetic variants in IL6R known to down-regulate IL-6 signalling are associated with improved Coronavirus Disease 2019 (COVID-19) outcomes, a finding later confirmed in randomised trials of IL-6 receptor antagonists (IL6RAs). We hypothesised that blockade of IL6R could also improve outcomes in sepsis. METHODS AND FINDINGS: We performed a Mendelian randomisation (MR) analysis using single nucleotide polymorphisms (SNPs) in and near IL6R to evaluate the likely causal effects of IL6R blockade on sepsis (primary outcome), sepsis severity, other infections, and COVID-19 (secondary outcomes). We weighted SNPs by their effect on CRP and combined results across them in inverse variance weighted meta-analysis, proxying the effect of IL6RA. Our outcomes were measured in UK Biobank, FinnGen, the COVID-19 Host Genetics Initiative (HGI), and the GenOSept and GainS consortium. We performed several sensitivity analyses to test assumptions of our methods, including utilising variants around CRP and gp130 in a similar analysis. In the UK Biobank cohort (N = 486,484, including 11,643 with sepsis), IL6R blockade was associated with a decreased risk of our primary outcome, sepsis (odds ratio (OR) = 0.80; 95% confidence interval (CI) 0.66 to 0.96, per unit of natural log-transformed CRP decrease). The size of this effect increased with severity, with larger effects on 28-day sepsis mortality (OR = 0.74; 95% CI 0.47 to 1.15); critical care admission with sepsis (OR = 0.48, 95% CI 0.30 to 0.78) and critical care death with sepsis (OR = 0.37, 95% CI 0.14 to 0.98). Similar associations were seen with severe respiratory infection: OR for pneumonia in critical care 0.69 (95% CI 0.49 to 0.97) and for sepsis survival in critical care (OR = 0.22; 95% CI 0.04 to 1.31) in the GainS and GenOSept consortium, although this result had a large degree of imprecision. We also confirm the previously reported protective effect of IL6R blockade on severe COVID-19 (OR = 0.69, 95% CI 0.57 to 0.84) in the COVID-19 HGI, which was of similar magnitude to that seen in sepsis. Sensitivity analyses did not alter our primary results. These results are subject to the limitations and assumptions of MR, which in this case reflects interpretation of these SNP effects as causally acting through blockade of IL6R, and reflect lifetime exposure to IL6R blockade, rather than the effect of therapeutic IL6R blockade. CONCLUSIONS: IL6R blockade is causally associated with reduced incidence of sepsis. Similar but imprecisely estimated results supported a causal effect also on sepsis related mortality and critical care admission with sepsis. These effects are comparable in size to the effect seen in severe COVID-19, where IL-6 receptor antagonists were shown to improve survival. These data suggest that a randomised trial of IL-6 receptor antagonists in sepsis should be considered.
引用
- Hamilton FW, Thomas M, Arnold D, et al. Therapeutic potential of IL6R blockade for the treatment of sepsis and sepsis-related death: A Mendelian randomisation study. PLoS Med. 2023. PMID: 36716318. doi:10.1371/journal.pmed.1004174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。